Corbus Pharmaceuticals Holdings, Inc. announced the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002), a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4. The Phase 1 portion of the open label study design (NCT06265727), being conducted in the U.S. and Europe, will evaluate the safety, efficacy and pharmacokinetics (PK) of CRB-701 in participants with advanced solid tumors associated with high Nectin-4 expression. The Phase 1 trial initiates with dose escalation followed by dose optimization and concludes with dose expansion to determine the recommended Phase 2 dose.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.02 USD | +8.80% | -7.27% | +645.36% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+645.36% | 473M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-0.29% | 22.1B | |
-9.28% | 18.34B | |
-41.70% | 16.59B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- CRBP Stock
- News Corbus Pharmaceuticals Holdings, Inc.
- Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC